Chimpanzee adenovirus vector-based avian influenza vaccine completely protects mice against lethal challenge of H5N1

详细信息    查看全文

• 作者：Tao Cheng ; Xiang Wang ; Yufeng Song ; Xinying Tang ; Chao Zhang ; Hongbo Zhang ; Xia Jin ; ^{xjin@ips.ac.cn" class="auth_mail" title="E-mail the corresponding author} ; Dongming Zhou ; ^{dmzhou@sibs.ac.cn" class="auth_mail" title="E-mail the corresponding author}
• 关键词：HPAI ; highly pathogenic avian influenza ; RDE ; receptor destroying enzyme ; AdHu5 ; human adenovirus serotype 5 ; HA ; haemagglutinin ; AdC7 ; chimpanzee adenovirus serotype 24 ; LD50 ; median lethal dose
• 刊名：Vaccine
• 出版年：2016
• 出版时间：22 September 2016
• 年：2016
• 卷：34
• 期：41
• 页码：4875-4883
• 全文大小：2326 K

文摘

Highly pathogenic avian H5N1 viruses may give rise to the next influenza pandemic due to their reassortment and mutation of the genome. Vaccine against this virus is important for coping with its potential threat. Chimpanzee adenovirus (Ad) vectors are a novel type of vaccine vectors that share the advantages of human serotype Ad vectors but without being affected by pre-existing human neutralizing antibody to the vaccine vector. Based on a replication-deficient chimpanzee Ad vector, AdC7, we generated a novel H5N1 vaccine candidate AdC7-H5HA that expresses H5N1 Hemagglutinin (HA). When tested in mice, the vaccine significantly reduced the virus load and pathological lesions in the lung tissues, and conferred complete protection against lethal challenge by a homologous virus. Mechanistically, the AdC7-H5HA vaccine can induce both HA-specific humoral and cell-mediated immune responses in mice. Also, sera transfer experiments demonstrated that neutralizing antibodies alone could provide protection. In conclusion, our results show that chimpanzee Ad vector expressing influenza virus HA may represent a promising vaccine candidate for H5N1 viruses and other influenza virus subtypes.